Skip to content
ChickenStockChickenStock
Research048410
Hyundai Bioscience logo

Hyundai Bioscience (048410) stock

KOSDAQ · Cosmetics

KRW 6,1700.00%(0)

As of Nov 16, 3:19 PM KST

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-20.81x

Net loss — not comparable

P/B

5.76x

P/S

179.30x

Earnings

Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.

Quarters and year-to-date
PeriodRevenueOperating profitNet incomeRevenue YoY
Q2 2026Consolidated · Filed Oct 2, 2026KRW 500 million-KRW 5.5 billion-KRW 11.6 billion+56.2%
Q1 2026Consolidated · Filed May 15, 2026KRW 300 million-KRW 4.7 billion-KRW 5.3 billion-54.2%
Q4 2025Consolidated · Filed Mar 30, 2026KRW 1.9 billion-KRW 4.4 billion-KRW 4.7 billion—
Q3 2025Consolidated · Filed Nov 14, 2025KRW 600 million-KRW 4.6 billion-KRW 7 billion+20.6%
Q2 2025Consolidated · Filed Aug 25, 2025KRW 300 million-KRW 4.8 billion-KRW 4.3 billion-96.4%
Q1 2025Consolidated · Filed Aug 25, 2025KRW 700 million-KRW 4.3 billion-KRW 6.1 billion-86.0%
Fiscal years
PeriodRevenueOperating profitNet incomeRevenue YoY
FY2025Consolidated · Filed Mar 30, 2026KRW 3.5 billion-KRW 18.2 billion-KRW 22.1 billion—
FY2024Consolidated · Filed Aug 25, 2025KRW 15.1 billionKRW 800 million-KRW 6.9 billion—
  • Q2 2026 is computed as H1 2026 minus Q1 2026.
  • Q4 2025 is computed as FY2025 minus 9M 2025.
  • Q3 2025 is computed as 9M 2025 minus H1 2025.
  • Q2 2025 is computed as H1 2025 minus Q1 2025.
Original filing (DART)

Short selling and securities lending

Short sales as a share of trading value, the reported short position and the securities lending balance.

Short-sale share
4.81%
Of trading value on Nov 13, 2026
Short-sale value
KRW 1.01 billion
Previous 20-day average 8.01%
Net short position
3,851,708 shares
As of Nov 11, 2026 · reported with a two-trading-day lag
Lending balance
11,366,835 shares
As of Nov 13, 2026 · 11.78% of listed shares
Recent short-sale days
DateShareValue
Nov 13, 20264.81%KRW 1.01 billion
Nov 12, 202612.44%KRW 350 million
Nov 11, 20266.88%KRW 240 million
Nov 10, 20264.16%KRW 120 million
Nov 9, 202613.16%KRW 530 million
Nov 6, 20268.32%KRW 490 million
Nov 5, 20269.06%KRW 430 million
Nov 4, 20268.05%KRW 320 million
Nov 3, 202612.17%KRW 400 million
Nov 2, 20266.10%KRW 300 million

The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.

Hyundai Bioscience (048410) stock information

KOSDAQ

Hyundai Bioscience (048410) is listed on KOSDAQ. Its market capitalization is about KRW 595.4 billion. On trailing-twelve-month earnings the P/E ratio is -20.81, and the P/B ratio is 5.76. Return on equity is -27.7%. These figures are computed in-house from official filings and are reference information only.

Hyundai Bioscience — frequently asked questions

What is the P/E ratio of Hyundai Bioscience (048410)?
On a trailing-twelve-month basis, 048410 trades at a P/E ratio of -20.81. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Hyundai Bioscience?
048410 has a market capitalization of about KRW 595.4 billion. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.